Conversely, those whom are long the sector and looking to aggressively hedge in the short term if not take the other side of the recent rally can potentially look to BIS (ProShares UltraShort NASDAQ Biotechnology, Expense Ratio 0.95%).

Earnings releases are expected in the member components of these ETFs in the near term, with AMGN for example reporting on 4/23 and REGN on 4/25 to name a few, so it will be interesting to see in coming weeks if fundamental results are in line with the street’s expectations as the stocks are clearly pricing in positive quarters for these names.

iShares NASDAQ Biotech

For more information on Street One ETF research and ETF trade execution/liquidity services, contact Paul Weisbruch at